Why a new clinical trial landscape demands greater collaboration and flexibility

Travis Caudill of Worldwide writes that clinical research professionals have witnessed a shift in the industry’s approach to clinical trials over the past decade. Large-scale, global trials that encompass hundreds of sites and many thousands of patients continue to give way to more narrowly defined studies focused on rare diseases, orphan indications, and the promise of genetic-level advances. This shift not only puts patient access at a premium but also forces us to reconsider our site selection values.